Hematological and Biochemical Action of Tiazofurin (NSC 286193) in a Case of Refractory Acute Myeloid Leukemia

Cancer Research

Volumn 47, Issue 18, 1987, Pages 4988-4991

  Tricot, Guido J ^a   Jayaram, Hiremagalur N ^a   Nichols, Craig R ^b   Pennington, Kenneth ^b   Lapis, Elizabeth ^b   Weber, George ^b   Hoffman, Ronald ^b  

^a Laboratory for Experimental Oncology ^*  (United States)

^b St Elizabeth Medical Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ANTILEUKEMIC AGENT; TIAZOFURIN;

ACUTE GRANULOCYTIC LEUKEMIA; ADVERSE DRUG REACTION; BLOOD AND HEMOPOIETIC SYSTEM; CANCER CHEMOTHERAPY; CASE REPORT; DRUG EFFICACY; DRUG SENSITIVITY; HUMAN; THERAPY;

ANTINEOPLASTIC AGENTS; BONE MARROW; GUANOSINE TRIPHOSPHATE; HUMAN; LEUKEMIA, MYELOCYTIC, ACUTE; MALE; MIDDLE AGE; RIBAVIRIN; RIBONUCLEOSIDES; SUPPORT, U.S. GOV'T, P.H.S.;

EID: 0023241646     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: None     Document Type: Article

References (15)

1. Lewis, J. P. Clinical trials of adult acute nonlymphocytic leukemia: evidence of progress. Cancer Treat. Rev. 12: 133–145, 1985.
2. Preisler, H. D. An integrated approach to the study and treatment of acute myelocytic leukemia. In: C. D. Bloomfield (ed.), Adult Leukemias 1, pp. 155–197. The Hague, The Netherlands: Martinus Nyhoff Publishers, 1982.
3. Robins, R. K., Srivastava, P. C., Narayanan, V. L., Plowman, J., and Paull, K. D. 2-β-D-Ribofuranosylthiazole-4-carboxamide, a novel potential antitumor agent for lung tumors and metastases. J. Med. Chem. 25: 107–108, 1982.
4. Ahluwalia, G. S., Jayaram, H. N., Plowman, J. P., Cooney, D. A., and Johns, D. G. Studies on the mechanism of action of 2-β-D-ribofuranosylthiazole-4-carboxamide. V. Factors governing the response of murine tumors to tiazofurin. Biochem. Pharmacol., 33: 1195–1203, 1984.
5. O'Dwyer, P. J., Shoemaker, D. D., Jayaram, H. N., Johns, D. G., Cooney, D. A., Marsoni, S., Malspeis, L., Plowman, J., Davignon, J. P., and Davis, R. D. Tiazofurin, a new antitumor agent. Invest. New Drugs, 2:79-84,1984.
6. Lui, M. S., Faderan, M. A., Liepnieks, J. J., Natsumeda, Y., Olah, E. Jayaram, H. N., and Weber, G. Modulation of IMP dehydrogenase activity and guanylate metabolism by tiazofurin (2-β-D-ribofuranosylthiazole-4-carboxamide). J. Biol. Chem., 259: 5078-5082,1984.
7. Cooney, D. A., Jayaram, H. N., Gebeyehu, G., Betts, C. R., Kelley, J. A., Marquez, V. E., and Johns, D. G. The conversion of 2-β-D-ribofuranosylthiazole-4-carboxamide to an analogue of NAD with potent IMP dehydrogenase inhibitory properties. Biochem. Pharmacol., 31: 2133-2136,1982.
8. Jayaram, H. N., Dion, R. L., Glazer, R. I., Johns, D. G., Robins, R. K., Srivastava, P. C., and Cooney, D. A. Initial studies on the mechanism of action of a new oncolytic thiazole nucleoside, 2-β-D-ribofuranosylthiazole-4-carboxamide (NSC 286193). Biochem. Pharmacol., 31: 2371–2380, 1982.
9. Jayaram, H. N. Pillwein, K., Nichols, C. R., Hoffman, R., and Weber, G. Selective sensitivity to tiazofurin of human leukemic cells. Biochem. Pharmacol., 35: 2029–2032, 1986.
10. Carney, D. N., Ahluwalia, G. S., Jayaram, H. N., Cooney, D. A., and Johns, D. G. Relationship between the cytotoxicity of tiazofurin and its metabolism by cultured human lung cancer cells. J. Clin. Invest., 75; 175–182, 1985.
11. Melink, T. J., Von Hoff, D. D., Kuhn, J. G., Hersch, M. R., Steinson, L. A., Patton, T. F., Siegler, R., Boldt, D. H., and Clark, G. M. Phase 1 evaluation and pharmacokinetics of tiazofurin (2-β-D-ribofuranosylthiazole-4-carboxamide, NSC 286193). Cancer Res., 45:2859-2865, 1985.
12. Trump, D. L., Tutsch, K. D., Koeller, J. M., and Tormey, D. C. Phase I clinical study with pharmacokinetic analysis of 2-β-D-ribofuranosylthiazole-4-carboxamide (NSC 286193) administered as a five-day infusion. Cancer Res., 45:2853-2858, 1985.
13. Roberts, J. D., Stewart, J. A., McCormack, J. J., Krakoff, I. R., Culham, C. A., Hartshorn, J. N., Newman, R. A., Haugh, L. D., and Young, J. A. Phase I trial of tiazofurin administered by i.v. bolus daily for 5 days, with pharmacokinetic evaluation. Cancer Treat. Rep., 71: 141-149,1987.
14. Lucas, D. L., Webster, H. K., and Wright, D. G. Purine metabolism in myeloid precursor cells during maturation. J. Clin. Invest. 72: 1889–1900, 1983.
15. Sokoloski, J. A., Blair, O. C., and Sartorelli, A. C. Alterations in glycoprotein synthesis and guanosine triphosphate levels associated with the differentiation of HL-60 leukemia cells produced by inhibitors of inosine 5’-phosphate dehydrogenase. Cancer Res., 46: 2314–2319, 1986.